2958

Journal of Lipid Research Volume 51, 2010
Cell culture
Human primary aortic endothelial cells (HAEC) were obtained from Lonza and maintained in endothelial cell growth medium [EGM-MV Bullet Kit = EBM medium + growth supplements + FCS (Lonza)] supplemented with 50 IU/ml penicillin and 50 µg/ml streptomycin. Cells were cultured in gelatin coated dishes at 37°C in a 5% CO 2 humidifi ed atmosphere and were used for experiments from passage 5 to 10. Cells were seeded (75000/well) in 12-well plates 48 h before exposure to LPC.
LPC treatment of HAEC
Initial time-and concentration-dependent experiments revealed that in a serum-free medium in the absence of BSA, all tested LPC at concentrations up to 10 µM were not toxic to HAEC (for incubations up to 8 h), as determined by monitoring the release of lactate dehydrogenase (LDH) using the cytotoxicity detection kit (LDH) (Roche, Mannheim, Germany).
At 48 h after plating, cells were washed with PBS and incubated with EBM medium without supplements and serum for 3 h. This medium is referred to as "serum-free medium" throughout the article. Thereafter, medium was removed and replaced with fresh serum-free medium supplemented with different concentrations of LPC alone or in some experiments along with AA or A23187. In some experiments, as indicated in the respective fi gure legends, LPC was applied in complex with BSA at a molar ratio of 1:1 and 5:1, respectively. Medium was collected in prechilled tubes at different time points following exposure to LPC, spun to remove cells, and used for lactate dehydrogenase (LDH) assay and measurement of prostanoids. Cells were washed with PBS and lysed in respective buffers for isolation of RNA or proteins.
Pharmacological inhibitors
During fi nal 30 min of incubation with serum-free medium prior to exposure to LPC as well as during exposure to LPC, HAEC were treated with respective pharmacological inhibitors (all from Calbiochem) or vehicle (DMSO). Specifi c COX-1 inhibitor SC-560 (100 nM), COX-2 inhibitor NS-398 (20 µM), and cPLA2 inhibitor (1 µM) 
Quantitative real-time PCR
RNA of cell extracts was isolated using the peqGOLD Total RNA Kit (Peqlab-biotechnology, Erlangen, Germany) according to the manufacturer's protocol, including on column DNase digestion. Then 1.5 µg of RNA were reverse transcribed using the Archive cDNA Kit (Applied Biosystems, Foster City, CA) and 0.7 U of an RNase Inhibitor (Qiagen, Hilden, Germany). RT-PCR analysis was performed in 384-well plates in a total volume of 4 µl containing 2 ng of original total RNA using the QantiFast SYBR green RT-PCR kit (Qiagen) and validated QuantiTect Primer Assays (Qiagen) according to the manufacturer's instructions for Light Cycler 480 instruments (Roche Diagnostics). In brief, after the initial heat activation step at 95°C for 5 min, cycling conditions consisted of 40 cycles of denaturation at 95°C for 10 s and combined annealing and extension at 60°C for 30 s. The PCR effi ciency of the target and housekeeping genes was determined by cDNA dilution series prepared from an untreated sample, and results were accordingly effi ciency-corrected with the LightCycler Relative Quantifi cation software (Roche Diagnostics, Basel, Switzerland). mRNA levels of COX-1 and COX-2 (Primer Assays QT00210280 and QT00040586) were normalized to human ␤ -2-microglobulin (Primer Assay QT01665006) and expressed as and prostanoids (EC) ( 14, 21, 22 ) , the role of the putative LPC receptors is still a matter of debate.
It is largely accepted that LPC may act via a subset of G protein-coupled receptors (GPCR), including GPR4, G2A (G2 accumulation), OGR1 (ovarian cancer G proteincoupled receptor 1), and TDAG8 (T cell death-associated gene 8), that are sensitive to both LPC and protons ( 23, 24 ) . Of these receptors, GPR4 shows the widest tissue distribution and is abundantly expressed in vascular endothelial cells where its expression is enhanced by infl ammation ( 25 ) . In contrast, G2A, whose cell surface expression and stabilization are enhanced by LPC ( 26 ) but whose proton-induced actions are antagonized by LPC ( 27 ) , is mainly expressed in lymphoid tissue, lymphocytes, and macrophages ( 24 ) . Although the initial papers were retracted due to failure to reproduce the binding of LPC to GPR4 and G2A, respectively, several studies have shown that LPC stimulates a variety of cellular activities dependent on GPR4 ( 25, 28, 29 ) . However, some studies that failed to observe the LPC actions in GPR4-expressing cells provided evidence for the capacity of GPR4 to sense extracellular protons, resulting in G-proteinmediated intracellular signaling and cAMP accumulation (30) (31) (32) .
Prostanoid biosynthesis involves oxidation and subsequent isomerization of unesterifi ed arachidonic acid (AA). The initial step of this metabolic pathway is the stimulusinduced release of AA from membrane phospholipids by phospholipase A2 (PLA2) enzymes, principally Ca 2+ -dependent cytosolic PLA2IVA (cPLA2), followed by conversion to prostaglandin H 2 (PGH 2 ) by either cyclooxygenase (COX)-1 or COX-2, both constitutively expressed by vascular endothelial cells (EC) (33) (34) (35) . PGH 2 is then converted to various prostanoids by the respective terminal prostanoid synthases ( 36, 37 ) .
Endothelial lipase is a phospholipase localized on the surface of vascular endothelial cells ( 38, 39 ) . We demonstrated previously that EL, by cleaving HDL-PC, generates substantial amounts of LPC 16:0, 18:1, 18:2, and 20:4, respectively ( 40 ) . As studies investigating the impact of LPC on prostanoid production have so far used 16:0 LPC exclusively ( 1, 14, 21, 22 ) , nothing is known about the impact of the length and degree of saturation of the LPC-acyl chain on prostanoid production. Therefore, the aim of the present study was to assess the impact of those LPC, found to be abundantly generated by EL, on PGI 2 production in vitro in HAEC and in vivo in mice.
MATERIALS AND METHODS
LPC
All LPC was purchased from Avanti Polar Lipids, and additional preparations of 18:2 and 20:4 were generated as described elsewhere ( 41 ) . LPC was dissolved and stored at Ϫ 20°C in chloroform/methanol under argon atmosphere. For experiments, required amounts of LPC were dried under a stream of nitrogen or argon and redissolved in PBS (pH 7.4) for cell culture experiments or in pyrogen-free saline for in vivo experiments. goat anti-COX-2 (Santa Cruz Biotechnology, M19, sc-1747, 1:100) and the HRP-labeled rabbit anti-goat IgG (Dako) as a secondary antibody. Protein signals were detected by ECL assay, and the intensity was normalized to actin (Pierce, ms Anti-Actin IgM: 1:4000) using densitometry.
Measurements of [Ca 2+ ] i
HAEC were seeded in 6-well plates. At 48 h after plating, cells were serum starved for 2 h and then loaded with 2 µM fura-2/AM for 60 min. After washing, cells were trypsinized and resuspended either in calcium buffer (138 mM NaCl, 1 mM MgCl 2 , 5 mM KCl, 10 mM Hepes, 10 mM Glucose, pH 7.4) or EGTA buffer (0.1 mM EGTA, 138 mM NaCl, 1 mM MgCl 2 , 5 mM KCl, 10 mM Hepes, 10 mM Glucose, pH 7.4). The ratio of fura-2 fl uorescence intensity at the two excitation wavelengths (340/380 ratio) was monitored spectrophotometrically in a stirring cuvette before and after the injection of 10 µM LPC. In some experiments, cells were resuspended in EGTA buffer followed by a preincubation with either 100 µM 2-APB for 2 min or with 2 µM U73122 for 5 min before the injection of LPC.
Experiments in mice
Following a 6 h fasting period, 10-12-weeks-old male C57Bl/6J mice (4-7 per group) were treated with 20 mg/kg LPC in 0.9% NaCl (or NaCl alone) via tail vein injection. After 20 h, blood was collected from the retro-orbital plexus into tubes containing indomethacin and EDTA, centrifuged immediately, and stored at Ϫ 70°C for measurements of 6-keto PGF 
Statistical analysis
Cell culture experiments were performed at least three times and values are expressed as mean plus SEM. Statistical significance was determined by the Student's unpaired t -test (twotailed) with application of Welch´s correction, where required. Group differences were considered signifi cant for P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***).
RESULTS
LPC induces PGI 2 production in HAEC
As determined by GC-MS/MS analysis, HAEC secrete 6-keto PGF 1 ␣ (a stable degradation product of PGI 2 ), thromboxane B 2 (TxB 2 ; a stable degradation product of TxA 2 ), PGF 2 ␣ , and PGE 2 ( Fig. 1A ) .
To examine the impact of LPC on endothelial PGI 2 production, HAEC were incubated with 10 µM LPC followed by EIA-based quantifi cation of 6-keto PGF 1 ␣ . As shown in relative ratio ( ⌬ ⌬ Ct). All samples were assayed in duplicate, and the average value was used for quantifi cation.
Prostanoid profi ling by GC-MS/MS
The spectrum of prostanoids produced by HAEC under basal conditions was determined by gas chromatographytandem mass spectrometry (GC-MS/MS) as described previously ( 42 ) . In brief, 10 µl deuterated internal standard mixture (about 1 ng of each PG) was added to 0.2-1 ml of each sample. After acidifi cation with formic acid (5%, v/v) to pH 2.6, a solution of 0.1 g methoxyamine hydrochloride in 1 ml sodium acetate (1.5 M, pH 5.0) was added. The prostanoid derivates were extracted with ethyl acetate/hexane (7:3, v/v). After evaporation, the residues were esterifi ed with a reaction mixture of acetone (80 µl), diisopropylamine (7 µl), and pentafl uorobenzyl bromide (6 µl) for 10 min at 40°C. Dried samples were then applied to TLC and developed in ethyl acetate/hexane (9:1, v/v). The target zones were scraped off (Rf = 0.03-0.39) and extracted with ethyl acetate. The extracts were then evaporated, derivatized twice with 10 µl BSTFA at 60°C, and analyzed using GC-MS/MS.
6-keto PGF 1 ␣ measurements by EIA
6-keto PGF 1 ␣ was measured in cell culture media and 5-fold diluted mouse plasma by a correlate-EIA kit (Cayman, Ann Arbor, MI) according to the manufacturer's protocol. Protein content of cell culture wells was initially determined to be equal for all treatments.
C-Arachidonic acid and C-6-keto PGF1 ␣ release
Cells were labeled with 14 C-AA (4 µM, spec. activity 58 mCi/ mmol) in complete medium for 20 h. Unbound 14 C-AA was removed by excessive washing in PBS supplemented with 1% BSA. After incubation in serum-free medium for 3 h, and facultative preincubation with 1 µM cPLA2 inhibitor for 30 min, cells were exposed to 50 µM LPC + 3.7 µM BSA (± cPLA2 inhibitor) for 20 min. Cell media were then collected, spun to remove cells, and immediately frozen at Ϫ 70°C until extraction. Cells were washed with PBS and lysed in 0.3 M NaOH/0.1% SDS. Aliquots of the cell lysates were mixed with scintillation cocktail, and the radioactivity was determined on a ␤ -counter (Beckman). Acidifi ed media were extracted with 2 vol of hexane/isopropanol (3:2, v/v), evaporated in the SpeedVac, and redissolved in chloroform, followed by TLC using ethylacetate/isooctane/water/ acetic acid (11:5:10:2, v/v) as a mobile phase. The signals corresponding to 14 C-AA and 14 C-6-keto PGF1 ␣ were visualized upon exposure of the TLC plates to a tritium screen (GE Healthcare) on the STORM imager. Quantifi cation was performed by densitometric volume report analysis or by liquid scintillation counting of cut out TLC spots corresponding to the comigrating AA-and 6-keto PGF1 ␣ -standard [visualized by spraying with primulin (0.01%, w/v) in acetone/water (60:40, v/v) and subsequent UV detection]. The amounts of 14 C-AA and 14 C-6-keto PGF1 ␣ released into medium were normalized to total cellular radioactivity measured by scintillation counting of cell lysates. 16:0 LPC, 2-fold by 18:1 LPC, and 1.6-fold by 20:4 LPC, upon 1 h incubation with 10 µM of LPC under our standard conditions (i.e., in serum-free medium without addition of NEFA-free BSA) ( Fig. 2B ) . The LPC failed to upregulate COX-2 mRNA when applied in combination with an equimolar amount of NEFA-free BSA (50 µM NEFA-free BSA + 50 µM LPC). When, based on the assumption that 1 mol of BSA binds 5 mol of LPC ( 43 ), the BSA concentration was adjusted to yield roughly 10 µM of free LPC (8.8 µM NEFA-free BSA + 50 µM LPC), the upregulation of COX-2 mRNA could be restored ( Fig. 2B ) .
Western blotting
LPC-induced 6-keto PGF 1 ␣ production is mediated by COX
LPC upregulates COX-2 mRNA but not COX-2 protein. The ability of both specifi c COX-1 (SC-560; 100 nM) and COX-2 (NS-398; 20 µM) inhibitors to prevent the LPC-mediated increase of 6-keto PGF 1 ␣ clearly demonstrated the involvement of both COX-enzymes ( NS-398), or vehicle (DMSO) for 30 min before their exposure to 10 µM LPC in serum free medium for 5 h. 6-keto PGF 1 ␣ concentration in cell culture supernatants was determined by EIA. Results shown are mean ± SEM of one representative experiment (n = 3). B: For determination of COX mRNA levels, HAEC were incubated either with 10 µM LPC, 50 µM LPC + 50 µM BSA (equimolar) or 50 µM LPC + 8.8 µM BSA ( ‫ف‬ 10 µM free LPC) for 1 h. Subsequently, RNA was isolated and the relative COX-2 mRNA abundance was determined by qRT-PCR as described in "Materials and Methods." Results shown are mean ± SEM of one representative experiment (n = 3). C: After 5 h of incubation with 10 µM LPC, HAEC COX-2 protein content was determined by 10% SDS-PAGE followed by immunoblotting using COX-2 and actin antibodies. Bands were visualized using appropriate secondary antibodies and an ECL substrate. A representative Western blot out of three is shown. COX, cyclooxygenase; HAEC, human aortic endothelial cell; LPC, lysophosphatidylcholine. 
] i elicited with all tested LPC ( Fig. 4C and supplementary Fig. IIIA, B Figs. 1 and 3 clearly showed that the capacity of 16:0 LPC to induce cPLA2-mediated AA release is unrelated to its capacity to elicit 6-keto PGF 1 ␣ production. Therefore, we examined whether 16:0 LPC compromises the conversion of AA to 6-keto PGF 1 ␣ . As shown in Fig. 5A , the production of 6-keto PGF 1 ␣ elicited by exogenous AA was unaltered by 16:0 LPC. The conversion of AA released (from cellular phospholipids) upon A23187 treatment to 6-keto PGF 1 ␣ was even promoted by 16:0 LPC ( Fig. 5A ) . Hence, the utilization of neither exogenous nor endogenous AA is compromised by 16:0 LPC. 1 ␣ production. To examine the capacity of 20:4 LPC to However, like COX-1 (supplementary Fig. IIB) , COX-2 protein was not increased after a 5 h incubation with LPC as determined by Western blotting ( Fig. 2C ) , leading us to the conclusion that COX protein upregulation could not account for the LPC-mediated increase of 6-keto PGF 1 ␣ .
20:4 LPC is a weak inducer of endogenous 6-keto PGF
LPC promote cPLA2-dependent AA release in HAEC.
To elucidate the underlying mechanism for LPC-elicited 6-keto PGF 1 ␣ production, we examined the role and contribution of cPLA2, the major PLA2 implicated in the generation of AA for PG synthesis. As shown in Fig. 3A , a specifi c cPLA2 inhibitor (see "Materials and Methods"; 1 µM) effi ciently decreased the LPC-elicited 6-keto PGF 1 ␣ production in HAEC, strongly indicating a role for cPLA2. To further examine the impact of LPC on cPLA2, 14 C-AA release was determined in HAEC. As shown in Fig. 3B , the highest (4.5-fold) induction of 14 C-AA release was obtained with 16:0 LPC and was less pronounced (2-and 2.7-fold) with LPC 18:1 and 20:4, respectively. The effects of all LPC could be decreased by preincubation with the specifi c cPLA2-inhibitor ( Fig. 3B ) , which also effi ciently decreased A23187-induced 14 C-AA release and 6-keto PGF 1 ␣ production in HAEC (not shown). As cPLA2 activation is postulated to be dependent on a transient increase in cytosolic calcium concentration [ ( Fig. 4A ). In the absence of extracellular Ca 2+ (EGTA), the increase in [Ca 2+ ] i triggered by 16:0 LPC was low and similar to that of 18:1 and 20:4, respectively ( Fig. 4B ) . Furthermore, EGTA did not alter the magnitude of the initial [Ca 2+ ] i peak elicited by 18:1 and 20:4 LPC; however, it rendered the signal transient ( Fig. 4B ) . Under EGTA-conditions, both U73122, a phospholipase C Fig. 3 . Role of cPLA2 in LPC-elicited 6-keto PGF 1 ␣ production and impact of LPC on cPLA2-mediated AA release. A: HAEC were preincubated with a specifi c cPLA2 inhibitor or vehicle (DMSO) for 30 min before exposure to 10 µM LPC in serum-free medium for 5 h. 6-keto PGF 1 ␣ in cell culture supernatants was quantifi ed by EIA. Results are mean ± SEM of seven separate experiments. B: HAEC were labeled with 14 C-AA for 20 h. After preincubation with cPLA2 inhibitor or vehicle (DMSO) for 30 min, cells were exposed to serum-free medium supplemented with 50 µM LPC + 3.7 µM BSA in the presence or absence of cPLA2 inhibitor for 20 min. Lipid extracts of cell media were separated by TLC and analyzed by densitometric quantifi cation of 4) has not been studied so far. Therefore, we examined the capability of those unsaturated LPC species, along with established 16:0 LPC, to modulate PGI 2 production in HAEC and in mice.
As found by MS analysis of cell media, HAEC produce PGI 2 , TXA 2 , PGF 2 ␣ , and PGE 2 . Considering the fact that HAEC, like human coronary artery endothelial cells (HCAEC) ( 44 ) , express PGI 2 synthase (PGIS), PGE 2 synthase (mPGES-1), and thromboxane synthase (TBXS) (not shown), it is conceivable that those prostanoids are products of enzymatic transformation of PGH 2 . However, we cannot completely exclude the possibility that a portion of the secreted prostanoids is generated by spontaneous, nonenzymatic transformation of PGH 2 ( 45 ) .
In the present study, we found remarkable acyl-chaindependent differences in the capability of LPC species to augment endothelial production of PGI 2 measured as stable degradation product 6-keto PGF 1 ␣ . In contrast to LPC 18:1 and 20:4, which were much more potent inducers of 6-keto PGF 1 ␣ than 16:0 LPC, LPC 18:2 was completely incapable of altering 6-keto PGF 1 ␣ production in HAEC. The observed 6-keto PGF 1 ␣ stimulation was sensitive to both COX-1-and COX-2-specifi c inhibitors, indicating that in HAEC exposed to LPC both COX enzymes are functionally coupled to PGIS ( 37 ) . In line with a previous fi nding ( 21 ) LPC augment PGI 2 production in mice. Finally, we tested the ability of LPC to promote the production of 6-keto PGF 1 ␣ in vivo. For this purpose, LPC was injected into the tail vein of fasted C57Bl/6J mice. The dose of injected LPC was 20 mg/kg to achieve plasma concentrations of approximately 10 µM of free LPC, after saturation of LPC binding sites of albumin and other plasma proteins. In accordance with in vitro data, 16:0, 18:1, and 20:4 LPC induced 6-keto PGF 1 ␣ formation in vivo ( Fig. 6 ), however, with a slightly different order of potency as found in HAEC.
DISCUSSION
Identifi cation of LPC 16:0, 18:1, 18:2, and 20:4 as major LPC species generated by the action of EL on HDL ( 40 ) prompted us to examine their impact on endothelial prostanoid production with the focus on PGI 2 . Whereas three studies provided evidence to support the role for 16:0 LPC as a modulator of endothelial prostanoid production ( 14, cPLA2 are used rather for reacylation of 16:0 LPC than as substrate for COX enzymes. Additionally, 16:0 LPC might interfere with functional coupling between cPLA2 and COX enzymes, which is a prerequisite for effi cient supply of AA released by cPLA2 to COX enzymes ( 37 ), or alternatively, it might attenuate the activity of PGIS, resulting in reduced conversion of released AA to PGI 2 . However, all these possibilities seem not to apply in our experimental and Rikitake et al. ( 22 ) demonstrated an increase in COX-2 protein upon exposure of HUVEC and bovine aortic endothelial cells (BAEC) to 16:0 LPC. The lack of COX-2 protein upregulation in our experimental model might be due to a lower responsiveness of HAEC in contrast to HUVEC and BAEC to LPC in terms of COX-2 induction. Additionally or alternatively, the amount and the form in which LPC is applied, namely 100 µM LPC in the presence of 5% FCS ( 21 ) or 20 µM LPC ( 22 ) versus 10 µM LPC in serum-free medium in our experimental system, might explain the discrepancy between our fi ndings and those of others. Our fi ndings provide clear evidence that the basal expression of COX-2 is suffi cient to accomplish LPC-elicited 6-keto PGF 1 ␣ production in HAEC. This is in line with the crucial role of basal endothelial COX-2 expression for the maintenance of vascular health, exemplifi ed by cardiovascular events upon the inhibition of COX-2 by "coxibs" (46) (47) (48) . Strikingly, 16:0 LPC compared with 18:1 and 20:4 LPC was the least potent inducer of 6-keto PGF 1 ␣ , whereas it was the most potent promoter of [Ca 2+ ] i increase and of cPLA2-mediated AA release. The profound activation of cPLA2 and concomitant AA release were also reported for 16:0 LPC in HUVEC; however, this study unfortunately did not address the impact of LPC on 6-keto PGF 1 ␣ production ( 14 ) . From our fi ndings, it appears that 16:0 LPC promotes AA release but reduces its full utilization toward the production of 6-keto PGF 1 ␣ . As 16:0 LPC is effi ciently converted to PC after uptake into cells ( 12 ) , it is conceivable that substantial amounts of AA released by activated channels independent of ER-empting ( 53 ), as well as by promoting membrane hyperpolarization due to the opening of Ca 2+ -activated K + channels ( 54 ) . Future studies should clarify the difference in the capability of the tested LPC species to elicit an increase in [Ca 2+ ] i and to identify the routes of Ca 2+ in HAEC. To demonstrate the physiologic relevance of our fi ndings, we injected LPC intravenously into mice. The amount of injected LPC was chosen to yield approximately 5-10 µM of free LPC, assuming scavenging by albumin and other carrier plasma proteins like ␣ -1-acid glycoprotein (AGP) ( 9 ) . Several studies have shown that the presence of albumin profoundly infl uences the bioactivity of LPC ( 41, (55) (56) (57) , clearly pointing to the requirement for the free, nonprotein-bound LPC. In accordance with those fi ndings was the inability of LPC to upregulate COX-2 mRNA when applied along with equimolar amounts of BSA and restoration of LPC-elicited COX-2 mRNA upregulation when BSA concentration was adjusted to yield approximately 10 µM of free LPC ( Fig. 2B ) . All LPC species elicited 6-keto PGF 1 ␣ production in mice, clearly arguing for their role in PGI 2 production in vivo. The order of potency was slightly different compared with HAEC, with the less pronounced effect of 18:1 LPC compared with 16:0 and 20:4 LPC. This discrepancy might be due to differences in metabolic and pharmacokinetic properties of 18:1 LPC compared with 16:0 and 20:4, like half-life in plasma, clearance by the liver, or scavenging by albumin, resulting in lower bioavailability and consequently diminished ability to promote 6-keto PGF 1 ␣ production in vivo. Of note, preliminary monitoring of 6-keto PGF 1 ␣ in mice showed a pronounced dissipation in basal plasma levels in untreated mice, explaining the variance observed in experimental groups upon LPC treatment.
Under physiological conditions, plasma albumin scavenges LPC, thus blunting its action on the vascular endothelium. However, it is very likely that under infl ammatory conditions when EL ( 58, 59 ) and other serum phospholipases ( 1, 2, 60 ) are upregulated, the excessive lipolysis in the plasma compartment raises the concentrations of FAs and LPC, leading to saturation of LPC binding sites on albumin and other plasma proteins and allowing the action of free LPC on vascular endothelium. The direct consequence of the action of LPC on vascular endothelium might be vasoprotective due to promotion of PGI 2 production. However, as the expression of PGE 2 , TxA 2 , and PGF 2 ␣ might also be altered by LPC in a similar manner as PGI 2 , further experiments are required to examine the impact of LPC on those prostanoids with opposite impact on vascular function.
To our knowledge, this is the fi rst study addressing the impact of the acyl-chain length and degree of saturation on the capacity of LPC to augment the formation of endothelial 6-keto PGF 1 ␣ . Here we show that the magnitude of increase in LPC-elicited 6-keto PGF 1 ␣ and the relative contribution of underlying mechanisms, including increase in [Ca 2+ ] i and cPLA2 activation as well as provision of exogenous substrate, are strongly related to acyl-chain length and degree of saturation. system, as experiments addressing a possible inhibitory effect of 16:0 LPC ( Fig. 5A ) on the conversion of either exogenous or endogenous AA to 6-keto PGF 1 ␣ production failed to provide evidence for an inhibitory effect of 16:0 LPC. In HAEC, 16:0 LPC even augmented A23187-induced 6-keto PGF 1 ␣ production. A very weak 6-keto PGF 1 ␣ response to 16:0 LPC, despite COX-2 upregulation, was also found in HUVEC ( 21 ) . Further experiments are required to clarify the failure of 16:0 LPC to induce a more effi cient 6-keto PGF 1 ␣ production. 20:4 LPC was the most potent inducer of 6-keto PGF 1 ␣ formation, whereas it was in the same range as 18:1 LPC regarding induction of [Ca 2+ ] i and cPLA2-mediated AA release. Accordingly, the induction of cPLA2-mediated AA release could not explain the marked 8.3-fold increase in 6-keto PGF 1 ␣ elicited with 20:4 LPC. Because the rate of 6-keto PGF 1 ␣ production elicited by 20:4 LPC was similar to that of AA, it is likely that 20:4 LPC serves as a source of AA for COX enzymes. This, in our opinion, makes the major contribution to the marked increase in 20:4 LPC-elicited 6-keto PGF 1 ␣ production. Beside different cellular lysophospholipases, cPLA2 may by its lysophospholipase activity ( 49 ) accomplish the release of AA from 20:4 LPC. Indeed, 20:4 LPC-elicited 6-keto PGF 1 ␣ production was signifi cantly decreased by cPLA2 inhibitor ( Fig. 3A ) , which probably refl ected the inhibition of both cPLA2 activities, the phospholipase activity involved in liberation of AA from cellular phospholipids and the lysophospholipase activity responsible for deacylation of 20:4 LPC. Importantly, the most potent inducer of 6-keto PGF 1 ␣ production among tested LPC, the 20:4 LPC, was a much weaker inducer of 6-keto PGF 1 ␣ production from endogenous AA than 16:0 LPC ( Fig. 5C ). These fi ndings corroborate further the role of 20:4 LPC as a provider of exogenous AA. We are aware that our conclusions regarding the role of 20:4 LPC as a source of AA are based on indirect experimental approaches, but the lack of a commercially available 20:4 LPC labeled in the AA moiety precludes the possibility of directly demonstrating the conversion of 20:4 LPC-derived AA to labeled 6-keto PGF 1 ␣ .
Regarding 18:2 LPC, we speculate that its failure to promote 6-keto PGF 1 ␣ production might be due to a negligible impact on cPLA2-mediated AA release and inability to act as a substrate provider for COX enzymes like 20:4 LPC. Indeed, 18:2 FA is a poor substrate for the elongation/ desaturation machinery in endothelial cells ( 50, 51 ) .
A transient increase in [Ca 2+ ] i is required for the translocation of cPLA2 from cytosol to the cellular membrane surface ( 52 ) . In line with this, we found that the extent of LPC-mediated AA release was fully related to the LPCelicited increase in [Ca 2+ ] i. . All tested LPC generated a biphasic increase in [Ca 2+ ] i with a rapid, IP 3 -triggered initial increase caused by the release of Ca 2+ from intracellular stores, which was similar for all LPC, followed by sustained infl ux of extracellular Ca Supplemental Material can be found at:
